BG106321A - Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists - Google Patents

Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Info

Publication number
BG106321A
BG106321A BG106321A BG10632102A BG106321A BG 106321 A BG106321 A BG 106321A BG 106321 A BG106321 A BG 106321A BG 10632102 A BG10632102 A BG 10632102A BG 106321 A BG106321 A BG 106321A
Authority
BG
Bulgaria
Prior art keywords
utilization
production
carboxylic acid
acid derivatives
receptor antagonists
Prior art date
Application number
BG106321A
Other languages
Bulgarian (bg)
Inventor
Wilhelm Amberg
Georg Kettschau
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG106321A publication Critical patent/BG106321A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to compounds of formula whereby the substituents have the meaning cited in the description. The invention also relates to the utilization of the said derivatives. 8 claims
BG106321A 1999-07-20 2002-01-18 Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists BG106321A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19933164A DE19933164A1 (en) 1999-07-20 1999-07-20 New carboxylic acid derivatives with 5,6 substituted pyrimidine ring, their production and use as endothelin receptor antagonists
PCT/EP2000/006293 WO2001005771A1 (en) 1999-07-20 2000-07-05 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
BG106321A true BG106321A (en) 2002-08-30

Family

ID=7914884

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106321A BG106321A (en) 1999-07-20 2002-01-18 Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists

Country Status (21)

Country Link
EP (1) EP1196394A1 (en)
JP (1) JP2003505377A (en)
KR (1) KR20020019550A (en)
CN (1) CN1367778A (en)
AR (1) AR030026A1 (en)
AU (1) AU6561500A (en)
BG (1) BG106321A (en)
BR (1) BR0012592A (en)
CA (1) CA2379545A1 (en)
CZ (1) CZ2002190A3 (en)
DE (1) DE19933164A1 (en)
HU (1) HUP0202646A3 (en)
IL (1) IL147666A0 (en)
MX (1) MXPA02000616A (en)
NO (1) NO20020254L (en)
PL (1) PL353165A1 (en)
SK (1) SK772002A3 (en)
TR (1) TR200200622T2 (en)
TW (1) TW555749B (en)
WO (1) WO2001005771A1 (en)
ZA (1) ZA200200333B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2575000T3 (en) * 2009-07-10 2016-06-23 Cadila Healthcare Limited Improved process for the preparation of ambrisentane
US20130060031A1 (en) 2010-03-15 2013-03-07 Natco Pharma Limited Process for the preparation of highly pure ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (en) * 1996-09-05 1998-03-12 Basf Ag New carboxylic acid derivatives, their production and use as mixed ET¶A¶ / ET¶B¶ receptor antagonists
JP2001521927A (en) * 1997-10-31 2001-11-13 ビーエーエスエフ アクチェンゲゼルシャフト Novel carboxylic acid derivatives having amide side chains, their preparation and use as endothelin receptor antagonists

Also Published As

Publication number Publication date
IL147666A0 (en) 2002-08-14
EP1196394A1 (en) 2002-04-17
NO20020254D0 (en) 2002-01-17
CA2379545A1 (en) 2001-01-25
CN1367778A (en) 2002-09-04
PL353165A1 (en) 2003-10-20
AU6561500A (en) 2001-02-05
KR20020019550A (en) 2002-03-12
ZA200200333B (en) 2003-04-30
HUP0202646A2 (en) 2003-02-28
HUP0202646A3 (en) 2003-03-28
CZ2002190A3 (en) 2003-08-13
TR200200622T2 (en) 2002-06-21
MXPA02000616A (en) 2002-08-30
WO2001005771A1 (en) 2001-01-25
AR030026A1 (en) 2003-08-13
BR0012592A (en) 2002-05-28
TW555749B (en) 2003-10-01
DE19933164A1 (en) 2001-01-25
NO20020254L (en) 2002-02-20
JP2003505377A (en) 2003-02-12
SK772002A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
CA2379026A1 (en) Substituted thiene-3-yl-sulphonylamino(thio)carbonyl-triazolin(thi)ones
CA2319275A1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
IL155875A0 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
TR200000333T2 (en) 4-aminopyrol (3,2-d) pyrimidines as Y receptor antagonists.
SE9702773D0 (en) Novel compounds
BG104831A (en) Heterocyclically substituted amides, their production and their use
TR199900486T2 (en) Azinyloxy and phenoxy-diaryl-carboxylic acid derivatives.
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
NO995114L (en) Fastener for connecting two parts to each other, as well as the use of the fastener
BG105847A (en) Calcilytic compounds
BG105689A (en) Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
MXPA04006571A (en) Fused bicyclic pyrimidine derivatives.
MXPA05009988A (en) 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists.
TR200001182T2 (en) New carbonic acid derivatives, their production and uses.
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG104022A (en) New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
BG106321A (en) Novel carboxylic acid derivatives with 5,6- substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
BG103502A (en) Heterocyclic derivatives of carboxylic acids, their preparation and application as endothelial receptor antagonists
MXPA05008601A (en) Benzamide derivatives as oxytocin agonists and vasopressin antagonists.
MXPA02001406A (en) Substituted heterocyclyl-2h-chromenes.
TR200001080T2 (en) 2-substituted 1,2-Benisothiazole derivatives and their antagonists of serroton
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
AU2001293791A1 (en) Process for the preparation of vitronectin receptor antagonists
IL134276A0 (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
BG106154A (en) Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, methods for their production and their use as endothelin receptor antagonists